AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29486723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-1 immunotherapy)
Number of subjects: 0
Study 29486723 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemokine and immunosuppressive molecule expression profiles
Number of subjects: 0
Study 29486737 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referrals
Number of subjects: 86
Study 29486737 — intervention group
Group type: COMPARATOR
Intervention: Provider-referrals
Number of subjects: 86
Study 29486737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall syndemic health problems
Number of subjects: 86
Study 29486784 — intervention group
Group type: EXPERIMENTAL
Intervention: Snacks (morning, afternoon, evening)
Number of subjects: 104265
Study 29486784 — intervention group
Group type: COMPARATOR
Intervention: Main meals
Number of subjects: 104265
Study 29486869 — intervention group
Group type: EXPERIMENTAL
Intervention: CORT (cortisol administration)
Number of subjects: 75
Study 29486869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29486918 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT)
Number of subjects: 30
Study 29486918 — intervention group
Group type: COMPARATOR
Intervention: Post-SIRT surgery
Number of subjects: 30
Study 29486918 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) followed by surgery
Number of subjects: 30
Study 29486998 — intervention group
Group type: EXPERIMENTAL
Intervention: Late menopause
Number of subjects: 373
Study 29486998 — intervention group
Group type: COMPARATOR
Intervention: Early menopause
Number of subjects: 373
Study 29486998 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in menopause by each year
Number of subjects: 373
Study 29487023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiation therapy
Number of subjects: 471
Study 29487023 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sexual aid utilization
Number of subjects: 471
Study 29487023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual aids usage after radiation therapy
Number of subjects: 471
Study 29487023 — intervention group
Group type: EXPERIMENTAL
Intervention: First-time use of sexual aids within 12 months
Number of subjects: 471
Study 29487023 — intervention group
Group type: EXPERIMENTAL
Intervention: First-time use of sexual aids more than 12 months after radiation therapy
Number of subjects: 471
Study 29487023 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who found sexual aids helpful at baseline
Number of subjects: 471
Study 29487023 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who developed erectile dysfunction but found aids helpful
Number of subjects: 471
Study 29487042 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro Vision Technology rehabilitation program
Number of subjects: 29
Study 29487046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetch app and digital body weight scale (DBWS)
Number of subjects: 55
Study 29487070 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD22 moxetumomab pasudotox (50 µg/kg every other day for 3 doses in 4-week cycles)
Number of subjects: 33
Study 29487070 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD22 moxetumomab pasudotox (50 µg/kg)
Number of subjects: 33
Study 29487193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-sensing sheath (PSS)
Number of subjects: 40
Study 29487193 — intervention group
Group type: COMPARATOR
Intervention: Radial arterial line (RAL)
Number of subjects: 40
Study 29487219 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (65 mg/m, twice-a-week dosing)
Number of subjects: 14
Study 29487221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation therapy after six cycles of chemotherapy
Number of subjects: 8
Study 29487556 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term pain treatment
Number of subjects: 0
Study 29487556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29487566 — intervention group
Group type: EXPERIMENTAL
Intervention: GADA positive T2DM patients
Number of subjects: 203
Study 29487566 — intervention group
Group type: EXPERIMENTAL
Intervention: Low C-peptide levels in T2DM patients
Number of subjects: 203
Study 29487566 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying
Number of subjects: 203
Study 29487566 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroparesis Cardinal Symptom Index (GCSI)
Number of subjects: 203
Study 29487697 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil- and irinotecan-based chemotherapy regimens (FOLFIRI or FOLFOXIRI) plus bevacizumab
Number of subjects: 0
Study 29487870 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon water therapy
Number of subjects: 35
Study 29487870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radon water therapy)
Number of subjects: 35
Study 29488122 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus cisplatin (XP)
Number of subjects: 40
Study 29488164 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 100
Study 29488164 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 100
Study 29488164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29488164 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 100
Study 29488303 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib (100 mg) alone
Number of subjects: 12
Study 29488303 — intervention group
Group type: COMPARATOR
Intervention: Glasdegib (100 mg) following rifampin (600 mg) pre-treatment
Number of subjects: 12
Study 29489073 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (pharmacotherapy for cannabis dependence)
Number of subjects: 23
Study 29489073 — intervention group
Group type: EXPERIMENTAL
Intervention: MJQQ (Marijuana Quit Questionnaire)
Number of subjects: 23
Study 29489427 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab or nivolumab (anti-PD-1/PD-L1 antibodies)
Number of subjects: 60
Study 29489559 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured breast implants
Number of subjects: 502
Study 29489633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy intervention for the prevention of venous ulcers
Number of subjects: 95
Study 29489906 — intervention group
Group type: EXPERIMENTAL
Intervention: Authorized Generic (AG)
Number of subjects: 0
Study 29489906 — intervention group
Group type: COMPARATOR
Intervention: Comparison Generics (EG)
Number of subjects: 0
Study 29490632 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICPIs)
Number of subjects: 4
Study 29490648 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based lifestyle modification intervention
Number of subjects: 50
Study 29490682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of Tranexamic Acid (TXA)
Number of subjects: 342
Study 29490682 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of Tranexamic Acid (TXA)
Number of subjects: 342
Study 29490682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 29490680 — intervention group
Group type: EXPERIMENTAL
Intervention: BESMILE-HF program plus usual medications
Number of subjects: 200
Study 29490680 — intervention group
Group type: COMPARATOR
Intervention: Usual medications
Number of subjects: 200
Study 29490690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 0.5 g
Number of subjects: 114
Study 29490690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 1 g
Number of subjects: 114
Study 29490690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 29490690 — intervention group
Group type: EXPERIMENTAL
Intervention: TA (0-2 g) in H patients
Number of subjects: 114
Study 29490690 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hemorrhagic (NH) group
Number of subjects: 114
Study 29490690 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pregnant (NP) women
Number of subjects: 114
Study 29490898 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis initiated in a mobile stroke unit (MSU) with computed tomography (CT).
Number of subjects: 37
Study 29490898 — intervention group
Group type: COMPARATOR
Intervention: Conventional pathway with transport to hospital for CT and thrombolysis as per current procedure.
Number of subjects: 37
Study 29490899 — intervention group
Group type: EXPERIMENTAL
Intervention: Samsung Galaxy S5
Number of subjects: 46
Study 29490899 — intervention group
Group type: EXPERIMENTAL
Intervention: Samsung Galaxy S6
Number of subjects: 46
Study 29490899 — intervention group
Group type: EXPERIMENTAL
Intervention: LG G3
Number of subjects: 46
Study 29490899 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices
Number of subjects: 46
Study 29490924 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of antiphospholipid antibodies (APAs)
Number of subjects: 307
Study 29490924 — intervention group
Group type: COMPARATOR
Intervention: Negative D-dimer results
Number of subjects: 307
Study 29491412 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 894999 (novel BET bromodomain inhibitor)
Number of subjects: 0
Study 29491412 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BI 894999 and CDK9 inhibitors
Number of subjects: 0
Study 29491490 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 77
Study 29493266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 111
Study 29493266 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 111
Study 29493399 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 462
Study 29493399 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a walking aid
Number of subjects: 462
Study 29493399 — intervention group
Group type: EXPERIMENTAL
Intervention: SwePASS total score ≤ 24
Number of subjects: 462
Study 29493399 — intervention group
Group type: EXPERIMENTAL
Intervention: SwePASS total score 25-30
Number of subjects: 462
Study 29493578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free DNA (cfDNA)
Number of subjects: 794
Study 29493578 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum screening (MSS)
Number of subjects: 794
Study 29493578 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum screening (MSS) in ART group
Number of subjects: 794
Study 29493578 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum screening (MSS) in spontaneous pregnancy (SP) group
Number of subjects: 794
Study 29493578 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA
Number of subjects: 794
Study 29493578 — intervention group
Group type: COMPARATOR
Intervention: MSS
Number of subjects: 794
Study 29493880 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCEL 2 stent (n = 208)
Number of subjects: 419
Study 29493880 — intervention group
Group type: COMPARATOR
Intervention: EXCEL stent (n = 211)
Number of subjects: 419
Study 29494181 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition lag training for 9 days
Number of subjects: 62
Study 29494181 — intervention group
Group type: COMPARATOR
Intervention: Active control program for 9 days
Number of subjects: 62
Study 29494351 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic sacrocolpopexy
Number of subjects: 36
Study 29494898 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 32
Study 29494898 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study 29494898 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS responders
Number of subjects: 32
Study 29494898 — intervention group
Group type: COMPARATOR
Intervention: Sham responders
Number of subjects: 32
Study 29494898 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders
Number of subjects: 32
Study 29496055 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed patient-specific surgical plates
Number of subjects: 10
Study 29496125 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood-onset schizophrenia (COS) patients
Number of subjects: 32
Study 29496125 — intervention group
Group type: COMPARATOR
Intervention: Nonpsychotic siblings of patients with COS
Number of subjects: 32
Study 29496167 — intervention group
Group type: EXPERIMENTAL
Intervention: Piscroside C
Number of subjects: 0
Study 29496473 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Number of subjects: 20
Study 29496499 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated proteomic classifier
Number of subjects: 685
Study 29497297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 0
Study 29497297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29497534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IgM immunoglobulin therapy (IVIG group)
Number of subjects: 0
Study 29497534 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29497535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose norepinephrine (≥ 416 μg/kg/week)
Number of subjects: 112
Study 29497535 — intervention group
Group type: COMPARATOR
Intervention: Low-dose norepinephrine (not specified)
Number of subjects: 112
Study 29497561 — intervention group
Group type: EXPERIMENTAL
Intervention: PROBE questionnaire
Number of subjects: 656
Study 29497747 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Number of subjects: 8
Study 29497956 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 42
Study 29498038 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (subcutaneous 300 mg weekly)
Number of subjects: 14
Study 29498296 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2215 (gilteritinib)
Number of subjects: 0
Study 29498296 — intervention group
Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 0
Study 29498742 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/r monotherapy (300/100 mg)
Number of subjects: 0
Study 29498742 — intervention group
Group type: COMPARATOR
Intervention: ATV/r triple therapy (300/100 mg + 2 NRTIs)
Number of subjects: 0
Study 29498742 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ATV/r monotherapy and ATV/r triple therapy
Number of subjects: 0
Study 29498742 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/r monotherapy
Number of subjects: 0
Study 29498923 — intervention group
Group type: EXPERIMENTAL
Intervention: IKZF1 deletions co-occurring with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion
Number of subjects: 991
Study 29498925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 113
Study 29499622 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress ulcer prophylaxis (SUP) using acid-suppression drugs
Number of subjects: 1416
Study 29499622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for >48 hours
Number of subjects: 1416
Study 29499622 — intervention group
Group type: EXPERIMENTAL
Intervention: History of UGIB
Number of subjects: 1416
Study 29499622 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of anticoagulants
Number of subjects: 1416
Study 29499622 — intervention group
Group type: EXPERIMENTAL
Intervention: SUP (acid-suppression drugs)
Number of subjects: 1416
Study 29499622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic drugs
Number of subjects: 1416
Study 29499645 — intervention group
Group type: EXPERIMENTAL
Intervention: Line-probe assays (LPA)
Number of subjects: 1128
Study 29499645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrosequencing (PSQ)
Number of subjects: 1128
Study 29499645 — intervention group
Group type: EXPERIMENTAL
Intervention: MODS
Number of subjects: 1128
Study 29499645 — intervention group
Group type: COMPARATOR
Intervention: MGIT
Number of subjects: 1128
Study 29499645 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQ
Number of subjects: 1128
Study 29499645 — intervention group
Group type: EXPERIMENTAL
Intervention: LPA
Number of subjects: 1128
Study 29499645 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQ and LPA
Number of subjects: 1128
Study 29499662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib at 800 mg/day
Number of subjects: 345
Study 29499662 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 345
Study 29499704 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status disclosure to male partners
Number of subjects: 100
Study 29499704 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status disclosure to family members
Number of subjects: 100
Study 29499704 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure rates among newly-diagnosed women
Number of subjects: 100
Study 29499704 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure rates among lost-to-follow-up women
Number of subjects: 100
Study 29499704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of divorce and intimate partner violence
Number of subjects: 100
Study 29499704 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance from healthcare workers
Number of subjects: 100
Study 29499710 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive home-based resistance training using an elastic band in addition to usual care
Number of subjects: 200
Study 29499710 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 200
Study 29499723 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased counts of circulating CD14 monocytes
Number of subjects: 0
Study 29499723 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating counts of inflammatory monocytes
Number of subjects: 0
Study 29499723 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating counts of patrolling monocytes
Number of subjects: 0
Study 29499740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose transdermal hydrogel MSCs (3 × 10)
Number of subjects: 90
Study 29499740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29499753 — intervention group
Group type: EXPERIMENTAL
Intervention: OMPSQ-G (Orebro musculoskeletal pain screening questionnaire - German version)
Number of subjects: 50
Study 29499753 — intervention group
Group type: EXPERIMENTAL
Intervention: OMPSQ-G
Number of subjects: 50
Study 29499766 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume (HV) HIIT group (40 min) with Mediterranean diet recommendations
Number of subjects: 177
Study 29499766 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume (LV) HIIT group (20 min) with Mediterranean diet recommendations
Number of subjects: 177
Study 29499766 — intervention group
Group type: COMPARATOR
Intervention: Attention control group with Mediterranean diet recommendations and physical activity without supervision
Number of subjects: 177
Study 29499850 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma concentrations of s-adenosylmethionine (SAM)
Number of subjects: 118
Study 29499850 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma concentrations of s-adenosylhomocysteine (SAH)
Number of subjects: 118
Study 29499850 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma concentrations of homocysteine (Hcy)
Number of subjects: 118
Study 29499850 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM:SAH ratio
Number of subjects: 118
Study 29500138 — intervention group
Group type: COMPARATOR
Intervention: Acute cellular rejection (ACR)
Number of subjects: 157
Study 29500138 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-mediated rejection (AMR)
Number of subjects: 157
Study 29500138 — intervention group
Group type: EXPERIMENTAL
Intervention: ddcfDNA levels
Number of subjects: 157
Study 29500154 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalised whole-brain white matter fractional anisotropy (WWM-FA) measured by diffusion tensor imaging
Number of subjects: 185
Study 29500154 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalised WWM-FA value lower than 0.91 in the validation cohort
Number of subjects: 185
Study 29500157 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush the Crave (CTC) app
Number of subjects: 1987
Study 29500160 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone injections and therapist-assisted progressive resistance training for 20 weeks
Number of subjects: 192
Study 29500160 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone injections for 20 weeks without physical exercise
Number of subjects: 192
Study 29500160 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo injections for 20 weeks combined with 16 weeks of progressive strength training
Number of subjects: 192
Study 29500160 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone injections for 20 weeks combined with 16 weeks of progressive strength training
Number of subjects: 192
Study 29500160 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections without physical exercise for 20 weeks
Number of subjects: 192
Study 29500161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led, mHealth-based intervention
Number of subjects: 136
Study 29500161 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study 29500162 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Extension Workers (CHEWs) providing contraceptive subdermal implants
Number of subjects: 8125
Study 29500162 — intervention group
Group type: COMPARATOR
Intervention: Nurses and midwives providing contraceptive subdermal implants
Number of subjects: 8125
Study 29500162 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEWs
Number of subjects: 8125
Study 29500162 — intervention group
Group type: COMPARATOR
Intervention: Nurses and midwives
Number of subjects: 8125
Study 29500202 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental caries during pregnancy
Number of subjects: 4826
Study 29500202 — intervention group
Group type: COMPARATOR
Intervention: Women without dental caries during pregnancy
Number of subjects: 4826
Study 29500207 — intervention group
Group type: EXPERIMENTAL
Intervention: High socioeconomic status (SES) as measured by Winkler-Stolzenberg Index (WSI) or family income
Number of subjects: 1206
Study 29500207 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity
Number of subjects: 1206